# A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

> **NCT01721746** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 405 (actual)

## Conditions studied

- Unresectable or Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** BMS-936558
- **DRUG:** Dacarbazine
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01721746
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-21
- **Primary completion:** 2016-02-16
- **Final completion:** 2020-12-29
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2022-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721746, "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT01721746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*